Join

Compare · NVS vs OGI

NVS vs OGI

Side-by-side comparison of Novartis AG (NVS) and Organigram Global Inc. (OGI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and OGI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $283.17B, about 1862.5x OGI ($152.0M).
  • Over the past year, NVS is up 26.9% and OGI is down 19.4% - NVS leads by 46.3 points.
  • OGI has hit the wire 3 times in the past 4 weeks while NVS has been quiet.
  • NVS has more recent analyst coverage (25 ratings vs 7 for OGI).
PerformanceNVS+26.90%OGI-19.40%
2025-06-04+0.00%2026-06-04
MetricNVSOGI
Company
Novartis AG
Organigram Global Inc.
Price
$148.44+3.30%
$1.08+1.41%
Market cap
$283.17B
$152.0M
1M return
+2.02%
-22.30%
1Y return
+26.90%
-19.40%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
0
3
Recent ratings
25
7
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

OGI

Organigram Global Inc.

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.